Search Results

To study families with multiple cases of lymphoproliferative disorders.

The National Cancer Institute (NCI) of the National Institutes of Health (NIH) is studying the causes of familial blood and lymph node cancers. The primary focus is on: Chronic lymphocytic leukemia (CLL), Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Waldenstrom’s macroglobulinemia (WM), and Multiple myeloma (MM).
The clinical evaluation includes a medical history and physical examination and may also entail disease-related laboratory or imaging studies. In certain cases, patients may be invited to visit the NIH Warren G. Magnuson Clinical Center in Bethesda, Maryland, for evaluation. Otherwise, study components can often be completed in or near the patient's home community.

Families with 2 or more living individuals in the family with a history of the same lymphoproliferative disorder

800-518-8474 https://dceg.cancer.gov/research/clinical-studies/blood-lymph-cancers

Closer to a Cure Inspires & Educates About Treatment Advances of Blood Cancers

FDA Approval of New Precision Medicine Therapy for Deadly Blood Cancer

Burlington Stores and LLS Bring Smiles to Those Touched by Blood Cancers

Optimizing Clinical Outcomes in Blood Cancers through Groundbreaking Translational Research

LLS Announces Expansion of Precision Medicine Approach to Fight Blood Cancer

FDA Approval of AML Therapy is a Significant Advance for Blood Cancer Patients

Jordin Sparks Joins Burlington Stores And LLS To Fight Blood Cancers

Love, Strength, Support: Sibling care in pediatric blood cancer journeys

Coping with Childhood Blood Cancer: The Power of Play and Creative Therapies for Families

Pegfilgrastim

Pegfilgrastim is FDA approved to

Paying Tribute to a Legacy: Executive Challenge Winners Recognized

This year’s Light The Night Executive Challenge ended with a bittersweet roundup of results. The winner, Stacey Weathers, former long-time executive director of The Leukemia & Lymphoma Society’s (LLS) New Jersey chapter, was tragically killed this past October when a tree fell on her car during a storm. Even though she isn’t here to celebrate with her LLS colleagues and family, her worthy achievement will be recognized as her legacy lives on.

A Powerful Force

MLB All-Star Player Designs Caps to Benefit LLS

The Leukemia & Lymphoma Society (LLS) hit a homerun when the Washington Nationals outfielder, Bryce Harper announced LLS will be a beneficiary of his limited edition, custom-designed baseball caps. Known for extraordinary talents in the outfield, Bryce’s talent as a hat designer is now getting recognition: He helped design the New Era caps which went on sale Wednesday, August 24.

Bendamustine hydrochloride

Bendamustine hydrochloride is FDA approved to treat people who have:

Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Reflections from the #ASH19 Meeting

As the 61st Annual ASH (American Society of Hematology) Meeting and Exhibition winds down here in Orlando, here are some thoughts on where things stand in the world of blood cancers.

Mitomycin

Mitomycin is FDA approved to treat people who have advanced adenocarcinoma of the stomach or pancreas in combination with other approved chemotherapeutic agents and as palliative treatment when other treatments have failed. This medication is sometimes prescribed for other uses such as bladder and lung cancer. Mitomycin sometimes causes a temporary loss of hair. After treatment has ended, normal hair growth should return.

The Leukemia & Lymphoma Society Honors Six Outstanding Blood Cancer Scientists with 2022 Achievement Awards

Jennifer Lewis (center) reunites with leaders of the Red Cross in Tena, Ecuador, during a visit to New York City.

Creating Great Investigators: LLS’s New Pathway To Medical Science For Underrepresented Minorities

Advocates walk in front of the California capitol in Sacramento

Patients' Medical Histories Shouldn't Determine Whether They're Insurable

All patients deserve access to quality, affordable health plans. Fortunately, most insurance cannot use patients' pre-existing conditions against them. But these protections don't exist for Medicare Supplement Insurance, known as Medigap. In fact, Medigap is one of the only types of health coverage that can charge patients more, or deny them coverage, due to their age or health status.

LLS is advocating for policies that would allow patients to enroll in Medigap—without paying higher rates—regardless of their health or age.

Making an IMPACT on hematology care in Georgia: The Georgia Blood Cancer Trials Network (BCTN)

Winship Cancer Institute is the only NCI-Designated Comprehensive Cancer Center in Georgia, the largest state by land area east of the Mississippi River, and 8th largest state by population. The Winship IMPACT program will leverage existing relationships throughout the state to bring hematology trials to patients in their communities. The goals are to strengthen our relationship with community sites and to increase opportunities for patients to access cutting edge trials throughout our state.